Author

E. Pros

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:differential expression· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Vidal· 2 shared A. Villanueva· 2 shared M. Saigi· 2 shared M. Sanchez-Cespedes· 2 shared A. Alay· 1 shared A. Andrade· 1 shared A. Dawson· 1 shared A. Gomez· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Vidal

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma

E. Aliagas, A. Alay, M. Martinez-Iniesta, M. Hernandez-Madrigal, D. Cordero, M. Gausachs, E. Pros, M. Saigi, S. Busacca, A. Sharkley, A. Dawson, R. Palmero, S. Padrones, S. Aso, I. Escobar, , E. Nadal

This study evaluates CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma, finding they reduce tumor growth and improve survival by inducing cell cycle arrest and senescence.

bioRxiv · Feb 8, 2021 · PreprintCancer Biology

SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade

O. A. Romero, A. Villarrubi, J. J. Alburquerque-Bejar, A. Gomez, A. Andrade, D. Trastulli, E. Pros, S. Verdura, L. Farre, J. F. Martin-Tejera, P. Llabata, A. Oaknin, M. Saigi, J. M. Piulats, X. Matias-Guiu, , M. Sanchez-Cespedes

This study identifies KDM6A/UTX and KDM6B/JMJD3 as therapeutic targets in SMARCA4-deficient cancers, showing that their inhibition reduces tumor viability in mouse models.

bioRxiv · Aug 7, 2020Cancer Biology